Retention rate of iguratimod with and without methotrexate in patients with rheumatoid arthritis.

Clinical course of patients with rheumatoid arthritis undergoing iguratimod with/without methotrexate. - Clinical course of patients with rheumatoid arthritis undergoing iguratimod with/without methotrexate; retrospectively observed trial.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041767

Enrollment

106

Registered

2020-09-11

Start date

2014-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 106 patients diagnosed with rheumatoid arthritis who were treated with Iguratimod during the period from 2014 to 2017.

Exclusion criteria

Exclusion criteria: Patients were excluded if they had been treated with biological DMARDs (bDMARDs). Patients with a connective tissue disease other than rheumatoid arthritis and patients previously treated with iguratimod were also excluded from the study.

Design outcomes

Primary

Measure	Time frame
Iguratimod retention rate with and without methotrexate in patients with rheumatoid arthritis at 24 weeks.	—

Countries

Japan

Contacts

Public ContactAsuka Inoue

Kindai University Nara Hospital Department of Hematology and Rheumatology

asuka@med.kindai.ac.jp0743770880

Outcome results